Is the Index Bubble Michael Burry Warned About Still Looming?


Image Credit: Vladamir Agofonkin (flickr)


Can Stock Market Index Enthusiasm Cause Costly Bubbles?

 

It has been 23 months since Michael Burry again caught the attention of the investment world by saying index funds are in a bubble. The discussion resurfaced again this morning in Barron’s article titled, The
Stock Market is Ridiculously Expensive, the Average Stock Isn’t.
   As we approach the two-year anniversary of his Bloomberg email interview, it’s important to remember what we learned from Michael Lewis’ book The Big Short about Burry and what investors in his Scion Asset Management service sign off on before they invest with him.

The first can be summed up in this way. When Burry was figuring out how to play the other side of a real estate bubble that few saw as clearly as himself, he went all in and then waited. His positions were built over a long period of time without drawing excessive attention to what he was doing. He informed his readers through his newsletter what he thought; however, unlike many other investment newsletters, it was not written in an alarmist fashion. The trades took a long time to play out.

The second useful tidbit we learned from The Big Short story is investors grew tired of waiting and were quite concerned he may be wrong. Some even got out of their agreements. Burry, along with a few others who shorted mezzanine level CMO tranches and CDOs, had confidence that the upward trend in housing wasn’t sustainable and would one day crumble.

Burry and others shorting securities tied to housing scrambled to grow their positions because they were concerned others would see what was plain as day to them.  They wanted to first fully load the boat with shorts on assets that appeared doomed.

 

What he Told Bloomberg

On September 4, 2019, Bloomberg News posted an article from a lengthy interview with Burry, whom many consider a savant investor. His view was startling at the time; he believed that the flood of money into index funds shows parallels with the pre-2008 bubble in collateralized debt obligations. Not one to just trade on hunches, Burry backed up what he said, saying index fund inflows are now distorting prices for stocks and bonds in much the same way that CDO purchases did for subprime mortgages. He warned the flows would reverse at some point and mentioned “it will be ugly” when they do.

Burry explained, “Like most bubbles, the longer it goes on, the worse the crash will be,” At the time he liked small-cap value stocks, one of the reasons is they tend to be under-represented in passive funds. His concerns included a lack of price discovery mechanisms functioning naturally, “Central banks and Basel III have more or less removed price discovery from the credit markets, meaning risk does not have an accurate pricing mechanism in interest rates anymore. And now passive investing has removed price discovery from the equity markets. The simple theses and the models that get people into sectors, factors, indexes, or ETFs and mutual funds mimicking those strategies — these do not require the security-level analysis that is required for true price discovery.

“This is very much like the bubble in synthetic asset-backed CDOs before the Great Financial Crisis in that price-setting in that market was not done by fundamental security-level analysis, but by massive capital flows based on Nobel-approved models of risk that proved to be untrue.”

 

“…In the Russell 2000 Index, for instance, the vast majority of stocks are lower volume, lower value-traded stocks. Today I counted 1,049 stocks that traded less than $5 million in value during the day. That is over half, and almost half of those — 456 stocks — traded less than $1 million during the day. Yet through indexation and passive investing, hundreds of billions are linked to stocks like this…” M.B.

 

Burry’s take on liquidity risk is also hard to poke holes in; he felt many stocks have been on a free ride saying, without building a large following on their own. He said “The dirty secret of passive index funds — whether open-end, closed-end or ETF — is the distribution of daily dollar value traded among the securities within the indexes they mimic. In the Russell 2000 Index, for instance, the vast majority of stocks are lower volume, lower value-traded stocks. Today I counted 1,049 stocks that traded less than $5 million in value during the day. That is over half, and almost half of those — 456 stocks — traded less than $1 million during the day. Yet through indexation and passive investing, hundreds of billions are linked to stocks like this. The S&P 500 is no different — the index contains the world’s largest stocks, but still, 266 stocks — over half — traded under $150 million today. That sounds like a lot, but trillions of dollars in assets globally are indexed to these stocks. The theater keeps getting more crowded, but the exit door is the same as it always was. All this gets worse as you get into even less liquid equity and bond markets globally.”

 

“…That sounds like a lot, but trillions of dollars in assets globally are indexed to these stocks. The theater keeps getting more crowded, but the exit door is the same as it always was. All this gets worse as you get into even less liquid equity and bond markets globally…” M.B.

 

Although he didn’t give a time frame in late 2019, he said it wouldn’t end well. He discussed how advisors are helping to build the problem by placing clients in indexed funds rather than more active management and lowering their fees to attract more assets; this helps the problem snowball. “Potentially making it worse will be the impossibility of unwinding the derivatives and naked buy/sell strategies used to help so many of these funds pseudo-match flows and prices each and every day. This fundamental concept is the same one that resulted in the market meltdowns in 2008. However, I just don’t know what the timeline will be. Like most bubbles, the longer it goes on, the worse the crash will be.” Said, Dr. Burry

Although it seemed surprising and even unbelievable at the time when the unraveling in the mortgage market began 13 years ago, it quickly became obvious that the market was allowed to become over-inflated (pronounced bubble) because the normal pricing mechanisms were stifled. Other investors eventually saw what Burry had seen much sooner; by then it was too late.

In an article this morning (July 28) in Barron’s, it seems they are beginning to make the same arguments that Michael Burry made almost two years ago. The Barron’s piece is titled, The Stock Market is Ridiculously Expensive, the Average Stock Isn’t.

The Barron’s Article Take on Today’s Market

The overriding claim in the reporting by Jacob Sonenshine is the stock market as a whole might look expensive, but there is value to be found in most companies in the S&P 500 (S&P). 

The reason given is the index weighs stocks with larger market caps greater than lower-valued companies. The S&P is currently trading at 21.4 times the aggregate forecast earnings per share of the companies that make it up. That, according to Barron’s is 43% above the long-term average of 15 times. If the influence of market cap was removed and all stocks were weighted equally, the average valuation would be 19 times forecasted earnings, according to Morgan Stanley, this is down from the high this year of 21 times. The decline resulted from sectors like energy selling off.

Investors are concerned that companies like Facebook, Apple, Amazon, Netflix, Google, and Microsoft are why the standard market cap weighting of the S&P appears expensive. According to Barron’s article, the six companies, with a combined market value of $9.4 trillion, account for a quarter of the index’s aggregate value.

They have outperformed the index recently, with an average gain of 4.9% in the past month. The S&P 500 is up 2.6% over that time. The thinking presented in the article is that investors who are positive about the economy are likely to be able to find value by picking stocks that demonstrate value rather than subjecting themselves to the lack of diversification weighted heavily toward those that are overvalued by traditional measures.

Take-Away

Don’t grow impatient with convictions, but timing is difficult. There is no certainty as to whether index fund investing has run its course and created unsustainable bubbles. However, the arguments made almost two years ago by someone who amassed great wealth back in 2008, shorting CDOs, is now being adopted by more mainstream thinking.

When evaluating small-cap stocks, remember your Channelchek registration allows you access to research and data on 6000 prospects that may fit your portfolio.

Paul Hoffman

Managing Editor, Channelchek

Suggested Reading:



Michael Burry Tweets Advice on Cryptocurrencies



Michael Burry Says COVID-19 Cure Worse Than the Disease





Why Microcaps are the New Small-Cap Stocks



Index Funds May Still Fall Apart Over Time

 

Sources:

https://www.barrons.com/articles/s-p-500-expensive-valuation-average-stock-51627417874?mod=hp_LEADSUPP_2

https://www.bloomberg.com/news/articles/2019-09-04/michael-burry-explains-why-index-funds-are-like-subprime-cdos

 

Stay up to date. Follow us:

 

Novel Ways to Combat Antibiotic Resistance



How to Train the Body’s Own Cells to Combat Antibiotic Resistance

 

Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work? This new strategy, called host-targeted defense, could help to solve antibiotic resistance problem.

Antibiotic resistance is a growing concern for global health. A recent report commissioned by the British government shows that every year globally around 700,000 people died due to infections caused by drug-resistant bacteria. The report also warned that, without action, the death toll could rise to 10 million globally and cost US$80 trillion to the global economy.

Drug resistance is a serious problem in the United States too. More than 23,000 people die every year due to multidrug-resistant pathogens and cost the country around $55 billion per year. The main culprits threatening the U.S. are methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE) and Clostridium difficile.

The CDC estimates that antibiotic-resistant pathogens cause more than 23,000 deaths annually in the United States. Source: Centers for Disease Control and Prevention. CDC webpage

The shortage of new antibacterial drugs in development to tackle the growing threat is a disturbing trend. A pathogen that is resistant to a drug reserved to treat infections when all others have failed is a particular concern. This is the case with carbapenem-resistant pathogen.

The decline in antibacterial drugs coupled with emergence of drug-resistant pathogens demands alternative approaches.

 

This article was republished with permission
from 
The
Conversation
, a news site dedicated to sharing ideas from academic experts. It
represents the research-based findings and opinions of
Zahidul Alam, Postdoctoral Fellow, University of Pennsylvania

 

In Malay Haldar’s lab, along with other projects, my colleagues and I are studying how factors in an animal host play a role in response to infections. To test the approach, we are doing this work using a mouse model of infections. Our aim is to find novel traits or factors of the host that can be targeted to boost an individual’s immune response high enough to kill the offending microbes. The host factor we are investigating is called Spi-C, a gene found in every cell of the human body.

Targeting Host Factors

My interest in host factors arose during my graduate studies. While working on my Ph.D. research project, I learned that host factors, a variety of traits intrinsic to humans, play a significant role in bacterial infections. This inspired me to investigate how the host’s immune system fights bacteria.

New insights into the host’s defense against pathogens have led researchers to explore a new strategy called host-directed therapy (HDT), a relatively recent idea that has only been around for about a decade.

The goal of HDT is to enhance and amplify the host’s immune response to kill pathogens, rather than relying exclusively on antibacterial drugs. By targeting host factors as well as delivering antibiotic treatment, HDTs deliver a double whammy.

 

Virtual Roadshow with Avivagen CEO Kym Anthony

This Virtual Road Show Replay features a formal corporate presentation from Avivagen CEO Kym Anthony. Afterwards, he is joined by Noble Capital Markets Senior Research Analyst Joe Gomes for a Q & A session featuring questions asked by the live audience throughout the event. Watch the replay, and get Noble’s research on VIVXF, as well as news and advanced market data at the link below.

View All Upcoming Road Shows

 

The body naturally responds to infections with inflammation, a process in which specific populations of immune cells attack and kill the invading bacteria by either eating them or zapping them with protein weapons. However, uncontrolled inflammation triggers the production of proteins that can cause multi-organ failure and can even kill the host. Therefore, controlling inflammation is crucial to combat pathogens as well as to protect the body from hyperinflammation.

HDTs include a suite of treatments that boost the host response to pathogens and also protect the host from exaggerated immune response. HDTs include cellular therapy, in which a specific population of bone marrow cells are injected into the host body to prevent excessive immune response and tissue injury. Another HDT involves commonly used drugs for noninfectious diseases. Statins and ibuprofen, for example, calm the host response to infections. Biologics, the complex molecule drugs produced by recombinant DNA technology, do this too by neutralizing small-sized proteins and reducing tissue damage. Nutritional products, such as vitamin D3, have also been shown to cause a host’s immune cells to release antibacterial substances that enhance pathogen killing.

HDTs in conjunction to antibacterial drugs show great promise in treating various multidrug-resistant pathogens, notably against Mycobacterium tuberculosis, the pathogen which causes tuberculosis, one of the top 10 causes of death worldwide.

 

Personalizing Treatments for Infections

In the last decade, researchers have made much progress in host factor research, leading to new therapeutic strategies.

One of them is personalized medicine, in which a genomic blueprint can determine an individual’s unique susceptibilities to diseases and choose appropriate therapies.

This concept is applied in noninfectious diseases like cancer. However, the application of the concept in infectious disease is very recent. Nonetheless, personalized medicine leads us to speculate why some individuals are more prone to infections than others. My colleagues and I believe that such differences may be caused by subtle differences in the DNA of the host factor genes. By connecting these differences, called polymorphisms, to the level of individuals’ vulnerability to infections, we hope that our research will contribute to the precision medicine of bacterial infections.

Our Quest for a Novel Host Factor

My colleagues in the Haldar lab and I are exploring the role of Spi-C in bacterial infection. Spi-C is essential for the development of a specific type of population of cells in the spleen that regulate the iron  storage in the body. Iron is essential for transporting oxygen in red blood cells.

But, during infections, bacteria also require iron. They need it for growth, and they compete with the host to get it. Hence, if we could alter the activity of the Spi-C gene, we might be able to deprive bacteria of this vital nutrient and thus stop the infections without harming the host.

In a recent paper, we summarized the effect of iron in host cells and its interactions with host factors in the presence or absence of infections.

In mice, we tested the role of host factor, Spi-C, as a way to defend the host. In this study we injected a chemical that is a component of the bacteria into the mice. We wanted to trigger changes that occur in the animal during a real bacterial infection.

Our preliminary results showed that the host factor is active in various organs of the mice treated with the chemical. We believe this activation plays a role in host-defense. And, indeed, we found that losing Spi-C activity increased the release of small-sized proteins that facilitate the host defense against pathogens compared to the cells that have normal Spi-C activity. We believe this change in small-sized proteins might protect the host from hyperinflammation in response to infection.

We believe that shifting of our thinking from pathogen-targeted therapy to host-directed therapy ushers in a new avenue of precision medicine, which could help to end the drug resistance crisis.

 

Suggested Content:



Antimicrobial Resistance, Problems and Investments



Essential Metals in the Health Sector





Finding Replacements for Petroleum Based Chemicals



Adaptive Phage Therapeutics (Video)

 

Stay up to date. Follow us:

 

QuickChek – July 28, 2021



Comtech Telecommunications Corp. Awarded $4.0 Million Contract Renewal with Channel Partner

Comtech Telecommunications announced that during its fourth quarter of fiscal 2021, its Location Technologies group was awarded a $4.0 million maintenance renewal agreement

Research, News & Market Data on Comtech Telecommunications

Watch recent presentation from Comtech Telecommunications



Great Bear Completes Phase 1 Grid Drilling to 450 m Depth at LP Fault: 440 Holes, 222,500 m Drilled Since May 2019 Discovery

Great Bear Resources announced an update regarding its ongoing fully funded $45 million 2021 exploration program at its 100% owned flagship Dixie Project in the Red Lake district of Ontario

Research, News & Market Data on Great Bear Resources

Watch recent presentation from Great Bear Resources



PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

PDS Biotechnology announced that its management team will present at several investor conferences during the third quarter of 2021

Research, News & Market Data on PDS Biotechnology

Watch recent presentation from PDS Biotechnology



Capstone Green Energy Wins Multiple Contracts, To Announce First Quarter Fiscal Year 2022 Financial Results

Announced that it received microturbine orders for several different customers in Austria and Germany

To Announce Its First Quarter Fiscal Year 2022 Financial Results on Wednesday, August 11, 2021

Research, News & Market Data on Capstone Green Energy

Watch recent presentation from Capstone Green Energy



CanAlaska Appoints Two New Board Members and Advisor

CanAlaska Uranium announced the appointment of Ms. Karen Lloyd and Mr. Geoff Gay to the Board of Directors of the Company

Research, News & Market Data on CanAlaska

 

Stay up to date. Follow us:

 

Release – Great Bear Completes Phase 1 Grid Drilling to 450 m Depth at LP Fault


Great Bear Completes Phase 1 Grid Drilling to 450 m Depth at LP Fault: 440 Holes, 222,500 m Drilled Since May 2019 Discovery

 

July 28, 2021 – Vancouver, British Columbia, Canada – Great Bear Resources Ltd. (the “Company” or “Great Bear”, TSX-V: GBR; OTCQX: GTBAF) today provides an update regarding its ongoing fully funded $45 million 2021 exploration program at its 100% owned flagship Dixie Project in the Red Lake district of Ontario.

Chris Taylor, President and CEO of Great Bear said, “We have now completed 440 drill holes at the LP Fault, and our Phase 1 drill grid is substantially complete to an average 450 metres depth along over 4 kilometres of strike length.  109 of the 440 drill holes totalling over 40,000 metres are currently in various stages of assay progress, with results expected regularly over the next 2 – 3 months.  Maiden mineral resource estimate modeling of the first 450 metres of mineralization from surface of the LP Fault is underway and is expected to be published no later than Q1 2022.”

The Company will now commence Phase 2 drilling, which will consist of: 1) Ongoing expansion drilling of the LP Fault below 450 metres depth and along strike, 2) any additional infill drilling of the upper 450 metres of the LP Fault that may be required after review, 3) expansion and infill drilling of the Hinge, Limb and Arrow zones, and 4) testing of new regional targets at Dixie.

More comprehensive Phase 2 drill plans, along with a description of which portions of the currently drilled mineralized zones will be included in the maiden mineral resource estimates, will be released after receipt and interpretation of current outstanding drill results.  Great Bear has approximately $83 million in cash on hand and is funded through 2022.  In total, Great Bear has completed 630 drill holes totaling 283,000 metres into all gold zones since beginning drilling at the Dixie Project in summer 2017.

 

Regional Forest Fire Update


Due to regional forest fire activity, on July 21st the Ministry of Northern Development, Mines, Natural Resources and Forestry (MNRF) issued a work suspension order for many construction, mining, mineral exploration and forestry related activities over an area extending from Marathon, Ontario to the Manitoba border, which includes Red Lake.  The order is expected to extend until local fire risk conditions improve.

In order to protect drill crews and Red Lake staff, Great Bear initiated a planned three-week suspension of drilling at the Dixie property on July 18th, coinciding with the conclusion of its Phase 1 grid drill program, and prior to the MNRF order being issued.  Phase 2 drilling is expected to begin on or around the week of August 9th, subject to fire safety conditions and modified work plan approvals from the MNRF at that time.  The current work suspension is not expected to significantly impact Great Bear’s progress at the Dixie Project, or maiden mineral resource estimation completion timing.

Chris Taylor continued, “We would like to sincerely thank all of the dedicated fire fighting crews for their courage and ongoing efforts to protect all of the affected regional communities, including Red Lake.  Special thanks also go out to the many groups of private volunteers, including Great Bear team members, local companies and members of all levels of government who are involved with supporting the fire fighting efforts.”

Forest fires and ongoing Ontario government work orders can be tracked at:

https://www.ontario.ca/page/forest-fires

About the Dixie Project

The Dixie Project is 100% owned, comprised of 9,140 hectares of contiguous claims that extend over 22 kilometres, and is located approximately 25 kilometres southeast of the town of Red Lake, Ontario. The project is accessible year-round via a 15 minute drive on a paved highway which runs the length of the northern claim boundary and a network of well-maintained logging roads.

The Dixie Project hosts two principal styles of gold mineralization:

  • High-grade gold in quartz veins and silica-sulphide replacement zones (Dixie Limb, Hinge and Arrow zones). Hosted by mafic volcanic rocks and localized near regional-scale D2 fold axes.  These mineralization styles are also typical of the significant mined deposits of the Red Lake district.
  • High-grade disseminated gold with broad moderate to lower grade envelopes (LP Fault).  The LP Fault is a significant gold-hosting structure which has been seismically imaged to extend to 14 kilometres depth (Zeng and Calvert, 2006), and has been interpreted by Great Bear to have up to 18 kilometres of strike length on the Dixie property.  High-grade gold mineralization is controlled by structural and geological contacts, and moderate to lower-grade disseminated gold surrounds and flanks the high-grade intervals.  The dominant gold-hosting stratigraphy consists of felsic sediments and volcanic units.

About Great Bear

Great Bear Resources Ltd. is a well-financed gold exploration company managed by a team with a track record of success in mineral exploration.  Great Bear is focused in the prolific Red Lake gold district in northwest Ontario, where the company controls over 200 km2 of highly prospective tenure across 4 projects, all 100% owned: The flagship Dixie Project, the Pakwash Property, the Sobel Property, and the Red Lake North Property, all of which are accessible year-round through existing roads.

 

Qualified Person and NI 43-101 Disclosure

Mr. R. Bob Singh, P.Geo, VP Exploration, and Ms. Andrea Diakow P.Geo, VP Projects for Great Bear are the Qualified Persons as defined by National Instrument 43-101 responsible for the accuracy of technical information contained in this news release.

 

ON BEHALF OF THE BOARD

“Chris Taylor”                                 

Chris Taylor, President and CEO

 

Investor Inquiries:

Ms. Jenni Piette,

Director, Sustainability and Stakeholder Relations

Tel: 604-646-8354

[email protected]

www.greatbearresources.ca

 

Cautionary note regarding forward-looking statements





This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes.




Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.




Such factors, among other things, include: impacts arising from the global disruption caused by the Covid-19 coronavirus outbreak, business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; fluctuations in spot and forward prices of gold or certain other commodities; change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); discrepancies between actual and estimated metallurgical recoveries; inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties.






Great Bear undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.




Release – PDS Biotechnology to Present Recent Phase 2 Human Clinical Data and On-Going Oncology Programs at Investor Conferences


PDS Biotechnology Announces Conference Call and Webcast to Present Second Quarter 2021 Financial Results

 

FLORHAM PARK, N.J., July 28, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management team will present at several investor conferences listed below during the third quarter of 2021. 

At the recent American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, interim data was presented in an oral session on PDS Biotech’s lead asset, PDS0101, in combination with two investigational immune-modulating agents being studied in two groups of advanced cancer patients. In the first group of patients who had failed treatment with chemotherapy and radiation, tumor reduction (objective response) was seen in 83% (5 of 6) of patients. In the second group, patients who in addition had failed treatment with checkpoint inhibitors, tumor reduction was seen in 58% (7 of 12) patients.

PDS0101 (Versamune®-HPV16) is an investigational immunotherapy candidate designed to treat cancers caused by infection with HPV16 (HPV16-positive cancers) by activating the immune system to produce in vivo CD8+ (killer) T-cells to target and kill tumors that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing. 

The upcoming investor conferences will offer leadership the opportunity to provide an update on both ongoing PDS0101 Phase 2 clinical trials, as well as preparations to move two other investigational compounds PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1) into human testing. The conference details are as follows:

BTIG Investor Conference
Date: Tuesday, August 10, 2021

HC Wainwright 23rd Annual Global Investment Conference
Date: Tuesday, September 14, 2021

Cantor Healthcare Conference
Date: Monday, September 27, 2021

AGP Fall Virtual Biotech & Specialty Pharma Conference
Date: Wednesday, October 13, 2021

A separate press release will be issued once presentation times become available. 

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune® platform with targeted antigens in HPV-expressing cancers. In partnership with Merck & Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contacts

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: [email protected]

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: [email protected]

Release – Comtech Telecommunications Corp. Awarded $4.0 Million Contract Renewal with Channel Partner


Comtech Telecommunications Corp. Awarded $4.0 Million Contract Renewal with Channel Partner

 

MELVILLE, N.Y.–(BUSINESS WIRE)–Jul. 28, 2021– 
July 28, 2021— 
Comtech Telecommunications Corp. (NASDAQ: CMTL), a global leading provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today, that during its fourth quarter of fiscal 2021, its Location Technologies group, a division of Comtech’s Commercial Solutions segment, was awarded a 
$4.0 million maintenance renewal agreement with a channel partner to continue to provide messaging application support for a 
U.S. tier-one mobile network operator.

“We are pleased to continue working with this customer of over 20 years to supply reliable text messaging services,” said  Fred Kornberg, Chairman of the Board and Chief Executive Officer of 
Comtech Telecommunications Corp. “Our commitment to this customer sustained the exponential growth in demand throughout the pandemic. We remain dedicated to providing the highest level of service even in the most challenging of times.”

The Location Technologies group of 
Comtech Telecommunications Corp. is a leading provider of precise device location, mapping and messaging solutions for public safety, mobile network operators, and enterprise solutions. Sold around the world to mobile network operators, government agencies, and Fortune 100 enterprises, our platforms locate, map, track and message. For more information, visit www.comtechlocation.com.

Comtech Telecommunications Corp. is a leading provider of next-generation 911 emergency systems and critical wireless communication technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions to customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

Comtech Investor Relations:
631-962-7005
[email protected]

Source: 
Comtech Telecommunications Corp.

Release – Capstone Green Energy to Announce Its First Quarter Fiscal Year 2022 Financial Results on Wednesday August 11 2021

 

Capstone Green Energy (NASDAQ:CGRN) to Announce Its First Quarter Fiscal Year 2022 Financial Results on Wednesday, August 11, 2021

 

VAN NUYS, CA / ACCESSWIRE / July 28, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) formerly Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) (“Capstone” or the “Company”), a global leader in carbon reduction and on-site resilient green energy solutions, announced today that on Wednesday, August 11, 2021, after market close, it expects to release full financial results for its first quarter of fiscal year 2022, ended June 30, 2021. Later that same day, at 1:45 p.m. Pacific Time (4:45 p.m. Eastern Time), Capstone will host a live webcast to discuss those results.

At the end of the conference call, Capstone will host a question-and-answer session to provide an opportunity for financial analysts to ask questions. Investors and interested individuals are invited to listen to the webcast by logging on to the Company’s investor relations webpage at www.capstonegreenenergy.com. A replay of the webcast will be available on the site for 30 days.

About Capstone Green Energy
Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: [email protected]. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on TwitterLinkedInInstagramFacebook, and YouTube.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
[email protected]

SOURCE: Capstone Green Energy Corporation

Release – CanAlaska Appoints Two New Board Members and Advisor


CanAlaska Appoints Two New Board Members and Advisor

 

Karen Lloyd and Geoff Gay Appointed to Board of Directors

Shane Shircliff Appointed to Advisory Board

Vancouver, British Columbia–(Newsfile Corp. – July 28, 2021) – CanAlaska Uranium Ltd. (TSXV: CVV) (OTCQB: CVVUF) (FSE: DH7N) (“CanAlaska” or the “Company”) is pleased to announce the appointment of Ms. Karen Lloyd and Mr. Geoff Gay to the Board of Directors of the Company, effective immediately. In addition, the Company is pleased to announce Mr. Shane Shircliff’s appointment to the Advisory Board of the Company.

Ms. Lloyd (B. Comm., M.B.A.) comes from a strong and significant strategy and marketing background across five different industries including mining, telecommunications, online payments, executive training and banking. This depth of experience comes from her employment with Telus Communications, Hongkong Bank of Canada and Cameco Corporation. Between 2009 and 2020, Ms. Lloyd managed a team of contract and inventory specialists to seamlessly fulfill global uranium sales generating annual revenue of between $1.8 and $2.4 billion for Cameco Corporation as a Director in Cameco’s Marketing team. In April 2021, Ms. Lloyd joined Kreos Aviation as Chief Operating Officer where she oversees all aspects of the Kreos operations including asset management, strategic alliances, flight operations, maintenance, fuel operations, marketing and sales, and business development.

Mr. Gay (BBA) is currently Chief Executive Officer of Athabasca Basin Development, an Indigenous-owned investment company based in Saskatchewan. Mr. Gay has been its executive leader, and subsequent CEO, since the company’s inception nineteen years ago and was instrumental in establishing and growing the company to where it is today. As CEO, Mr. Gay is responsible to articulate the vision of the partnership with a focus on creating value for the unit holders and leading the company in long term strategic planning and implementation, evaluating new opportunities for investment, assessing and mitigating risk, and overseeing all financial aspects of the partnership. Athabasca Basin Development is an investment company committed to building and investing in successful businesses. Since establishment, the company has grown to include partial or complete ownership in thirteen companies providing a wide range of services to the mining and resources industry, with consolidated revenues regularly exceeding $100M. In 2017, Mr. Gay was named Business Leader of the Year by Saskatchewan Chamber of Commerce at its annual ABEX awards.

Mr. Shircliff (B. Comm., M.B.A.), now appointed to CanAlaska’s Advisory Board, has over twenty years of experience in senior management and corporate director roles for both publicly traded and private companies, and has extensive experience with various publicly traded regulatory regimes. Mr. Shircliff’s breadth of expertise over his career includes negotiation, deal structure, due diligence and transacting mergers, acquisitions and divestitures totaling over one billion dollars in value. Industries of experience include logistics, finance, natural resources, exploration and mining, retail, real estate and construction. Mr. Shircliff has been directly involved with all aspects of developing resource projects encompassing lithium, uranium, gold, silver, industrial minerals, diamonds as well as oil and gas in a variety of countries. Mr. Shircliff is the founder and Chief Executive Officer of Clinworth Management Corp., a private company, which provides management, acquisition, divestiture and corporate development services to a wide range of clients. Clinworth most recently has been working with and advising clients in the areas of acquisitions, strategy, resources, retail, real estate and construction. In addition to industry clients, Clinworth continues to advise First Nations and their economic development entities on strategy, negotiation and growth opportunities.

The Company also announces that it has granted incentive stock options to Directors and Advisors of the Company to purchase up to 400,000 common shares of the Company pursuant to the Company’s share option plan. The options are exercisable for a period of three years at a price of $0.47 per share.

CanAlaska CEO, Cory Belyk, comments; “On behalf of the Board, it is my pleasure to welcome Karen, Geoff and Shane to the CanAlaska team. Each bring a depth of local and global knowledge across a multitude of industries, which will assist CanAlaska along its journey to discover the carbon-free energy sources that are now in demand world-wide.”

About CanAlaska Uranium

CanAlaska Uranium Ltd. (TSXV: CVV) (OTCQB: CVVUF) (FSE: DH7N) holds interests in approximately 214,000 hectares (530,000 acres), in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

On behalf of the Board of Directors
“Peter Dasler”
Peter Dasler, M.Sc., P.Geo.
President
CanAlaska Uranium Ltd.

Contacts:

Cory Belyk, Executive VP and CEO
Tel: +1.604.688.3211 x 306
Email: [email protected]

Peter Dasler, President
Tel: +1.604.688.3211 x 138
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Release – Capstone Green Energy Wins Multiple Contracts With Wastewater Treatment Plants in Austria and Germany

 

Capstone Green Energy Wins Multiple Contracts With Wastewater Treatment Plants in Austria and Germany

 

VAN NUYS, CA / ACCESSWIRE / July 28, 2021 / Capstone Green Energy Corporation(www.CapstoneGreenEnergy.com) (NASDAQ:CGRN), formerly Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) (“Capstone” or the “Company”), announced today that it received orders for several different customers in Austria and Germany to provide its microturbines as part of upgraded and expanded systems at multiple industrial and wastewater treatment plants. The orders, secured by long-time Capstone distributor Wels Strom, are expected to provide reliable, low maintenance energy for these critical infrastructure sites, several of which are repeat Capstone customers.

A total of eight C65 Microturbines and five C30s have been ordered. Five of the C65s will run on biogas and three on natural gas, while the C30s will all run on biogas. Because biogas is a waste byproduct that would otherwise need to be flared at these sites, the systems are expected to reduce emissions, while also saving on fuel costs.

In addition to the microturbine purchases, several customers have already signed 5- or 10-year service contracts provided by Capstone’s Factory Protection Plan (FPP). Through the FPP, maintenance costs are fixed, and both planned and unplanned repairs are covered for the life of the contract, thereby maintaining high performance and limiting long-term system costs.

“One of the big lessons of the global pandemic for these kinds of critical infrastructure sites was that they needed to operate without interruption, and often with limited personnel,” said Leopold Berger, Head of Energy Systems at Wels Strom. “So when it came to reliability and remote monitoring capabilities, Capstone Green Energy was the ideal choice,” added Mr. Berger.

“These orders are a healthy sign that our market is starting to rebound in Europe, in this case, specifically, Austria and Germany,” said Darren Jamison, President and Chief Executive Officer of Capstone Green Energy. “As we work with prospective customers on their near-term and long-term energy goals, we’re finding that there is greater interest in finding solutions that address both the issues of power security and the environment. For those reasons, wastewater treatment facilities are prime candidates for these types of system upgrades,” concluded Mr. Jamison.

About Capstone Green Energy
Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: [email protected]. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on TwitterLinkedInInstagramFacebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
[email protected]

SOURCE: Capstone Green Energy Corporation

Seanergy Maritime (SHIP) – Another Acquisition Closed, Leaving One to Go

Wednesday, July 28, 2021

Seanergy Maritime (SHIP)
Another Acquisition Closed, Leaving One to Go

Seanergy Maritime Holdings Corp., an international shipping company, provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. Seanergy Maritime Holdings Corp. is the only pure-play Capesize shipping company listed in the US capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of 10 Capesize vessels, with total capacity of approximately 1,748,581 dwt and an average fleet age of about 9.8 years. The Company is incorporated in the Marshall Islands with executive offices in Athens, Greece and an office in Hong Kong. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP” and class A warrants under “SHIPW”.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    One Cape delivery down, one to go. The acquisition of the Friendship, a 2009—built Cape, closed, which leaves only the Worldship closing to go. Debt of $13.0 million at Libor plus 300 bps was approved by an existing lender, with debt amortization of $2.8 million in year one, $1.5 million in years two through four and a balloon payment of $5.7 million due in 2025.

    2Q2021 results BMO out on July 29th and call scheduled for 10am EST.  Call number is 877-870-9135 and code is 5697340. EBITDA estimate is $10.1 million based on TCE rates of $19.5k/day …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Palladium One Mining Inc. (NKORF)(PDM:CA) – Tyko Nickel-Copper Project Area Enlarged with Purchase and Earn-In Agreements

Wednesday, July 28, 2021

Palladium One Mining Inc. (NKORF)(PDM:CA)
Tyko Nickel-Copper Project Area Enlarged with Purchase and Earn-In Agreements

Palladium One Mining Inc is a palladium dominant, PGE, nickel, copper exploration and development company. Its assets consist of the Lantinen Koillismaa and Kostonjarvi PGE-Cu-Ni projects, located in north-central Finland and the Tyko Ni-Cu-PGE and Disraeli PGE-Ni-Cu properties in Ontario, Canada. LK is targeting disseminated sulphide along 38 kilometers of favorable basal contact. The KS project is targeting massive sulphide within a 20,000-hectare land package covering a regional scale gravity and magnetic geophysical anomaly. Tyko is a 13,000-hectare project targeting disseminated and massive sulphide in a highly metamorphosed Archean terrain. Disraeli is a 2,500-hectare project targeting PGE-rich disseminated and massive sulphide in a highly productive Proterozoic mid-continent rift.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Expansion of the Tyko project. The Tyko Nickel-Copper project area has been increased to 24,550 hectares from 20,100 hectares with the purchase of new claims representing 3,500 hectares, along with two separate earn-in agreements representing an additional 950 hectares. These acquisitions follow the completion of the Phase II drill program which revealed high-grade nickel intercepts and significant exploration potential.

    Airborne geophysical survey completed.  An airborne versatile time-domain electromagnetic (VTEM) survey has been completed across the entire Tyko project. A key focus of the program is to trace the Smoke Lake sulphide lens to depth and identify the source of sulphide mineralization, along with identifying other zones of nickel-copper sulphide mineralization on the Tyko property. The results will be …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Flotek Industries (FTK) – Flotek Leases Out Part of Its Facilities

Wednesday, July 28, 2021

Flotek Industries (FTK)
Flotek Leases Out Part of Its Facilities

Flotek Industries, Inc. creates solutions to reduce the environmental impact of energy on air, water, land and people. Flotek Industries, Inc. is a technology-driven, specialty chemistry and data company that helps customers across industrial, commercial and consumer markets improve their Environmental, Social and Governance performance. Flotek’s Chemistry Technologies segment develops, manufactures, packages, distributes, delivers, and markets high-quality cleaning, disinfecting and sanitizing products for commercial, governmental and personal consumer use. Additionally, Flotek empowers the energy industry to maximize the value of their hydrocarbon streams and improve return on invested capital through its real-time data platforms and green chemistry technologies. Flotek serves downstream, midstream and upstream customers, both domestic and international. Flotek is a publicly traded company headquartered in Houston, Texas, and its common shares are traded on the New York Stock Exchange under the ticker symbol “FTK.” For additional information, please visit Flotek’s web site at www.flotekind.com.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Flotek announced a long-term agreement with Resolute Oil to lease out its 15-acre blending facility in Waller, TX. Terms of the agreement were not announced. Resolute will use the facility to blend white mineral oil which is used in a variety of industries from agriculture to food to cosmetics. Resolute will have the right to upgrade the facilities (perhaps to manufacture products for Kosher foods) and the option to renew the lease until 2036.

    The lease should not affect Flotek’s current operations.  Flotek has six operating facilities. Flotek’s other operating facilities are located in Texas (2), Oklahoma, Canada, and Europe. We do not believe the lease of the Waller plant will have an adverse impact on its ability to manufacture its oil service and cleaning products at current levels. By leasing out the facilities instead of selling …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Chakana Copper Corp (CHKKF)(PERU:CA) – Impressive Drill Results Among Four Targets at Soledad

Wednesday, July 28, 2021

Chakana Copper Corp (CHKKF)(PERU:CA)
Impressive Drill Results Among Four Targets at Soledad

Noble Capital Markets research on Chakana Copper Corp is published under ticker symbols CHKKF and PERU:CA. The price target is in USD and based on ticker symbol CHKKF. Chakana Copper Corp is a Canadian-based minerals exploration company that is currently advancing the high-grade gold-copper-silver Soledad Project located in the Ancash region of Peru, a highly favorable mining jurisdiction with supportive communities. The Soledad Project consists of high-grade gold-copper-silver mineralization hosted in tourmaline breccia pipes. A total of 33,353 metres of drilling has been completed to-date, testing nine (9) of twenty-three (23) confirmed breccia pipes with more than 92 total targets. Chakana’s investors are uniquely positioned as the Soledad Project provides exposure to several metals including copper, gold, and silver.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Latest drill results. Chakana Copper released results from 9 resource definition and exploration holes, representing 1,993.2 meters of drilling, at the Huancarama East, Paloma West, Bx1, and Bx7 tourmaline breccia pipe discoveries. Mineralization was encountered in all holes drilled. The drilling program continues to yield impressive results and affirm zones of massive sulfide at the Soledad project. To date, only 15 out of 110 targets on the Soledad property have been drill-tested.

    Initial resource estimate expected in Q4′ 2021.  Including drilling activities that commenced in August 2020, a total of 32,000 meters of drilling is anticipated through 2021. This includes 76 drill holes, representing 15,939.35 meters of drilling in the Paloma and Huancarama areas, for which results have been released. For the 26,000 meters of drilling planned in 2021, the company expects to …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.